Drug Pricing
Our work in Drug Pricing
-
Patients Would Give Up Over 5 Years of Life for Easier Treatments, Study Finds
A new study looks at the relationship between treatment burden and quality of life for individuals with CF and finds the burden of administering a treatment is a significant factor in patient preference.
Categorized in -
The Impact of the US Food and Drug Administration Chlorofluorocarbon Ban on Out-of-pocket Costs and Use of Albuterol Inhalers among Individuals with Asthma
In this study of the impact of the US Food and Drug Administration’s chlorofluorocarbon ban on out-of-pocket costs and utilization of albuterol inhalers, the researchers found that the ban led to large relative increases in out-of-pocket albuterol costs among privately insured individuals with asthma and modest declines in utilization.
Categorized in -
Do Statins Reduce the Health and Health Care Costs of Obesity?
This study found that, although statins are very effective medications for lowering the risk of obesity-associated illnesses, they do not significantly reduce the costs of obesity.
Categorized in -
Reverse Engineering Measures of Clinical Care Quality: Sequential Pattern Mining
In this study, the researchers hypothesized that, by using outcomes as a training signal, they could discover patterns of treatment that lead to better or worse than expected outcomes, and found that their framework improved the accuracy in survival analysis and facilitated discovery of patterns of care that improve outcomes.
Categorized in -
Evaluating the Economic Burden of Psoriasis in the United States
This study assessed the annual economic burden of psoriasis in the US and found that the economic burden is significant, with a majority coming from indirect costs.
Categorized in -
Antithrombotic Use in Nonvalvular Atrial Fibrillation (NVAF): Alignment between Guidelines and Emerging Evidence with Clinician Prescribing Preferences
This study surveyed physicians to determine how their preferences over antithrombotic therapies compare with current treatment guidelines and indirect treatment comparisons.
Categorized in -
Clozapine Revisited: Impact of Clozapine vs Olanzapine on Health Care Use by Schizophrenia Patients on Medicaid
In this evaluation of health care use and cost patterns for clozapine compared with olanzapine in the treatment of schizophrenia, the researchers found that clozapine increased duration of therapy and decreased risk of psychiatric hospitalization or suicide attempts compared to olanzapine, though increased drug costs and use of community mental health centers for complete blood count monitoring overwhelmed any offsetting savings.
Categorized in -
Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non–Small-Cell Lung Cancer
This study considers the value of providing access to new treatments on the basis of surrogate end points, and progression-free survival (PFS) in particular, likely varies considerably, and that payers and clinicians should carefully consider how to use PFS data in balancing potential benefits against costs in each particular disease.
Categorized in -
Clinical Evidence Inputs to Comparative Effectiveness Research Could Impact the Development of Novel Treatments
This study analyzed the impacts of a range of clinical evidence generation scenarios associated with comparative effectiveness research (CER) on pharmaceutical innovation, and found that changes in producer incentives from widespread CER evidence generation and use varied but often predicted large impacts on simulated outcomes in 2060.
Categorized in -
Quality-Adjusted Cost of Care: A Meaningful Way to Measure Growth in Innovation Cost Versus the Value of Health Gains
In this look at the quality-adjusted cost of care, which illustrates cost growth net of growth in the value of health improvements, measured as survival gains multiplied by the value of survival in colorectal cancer and multiple myeloma, the researchers document rapid cost growth and demonstrate starkly different answers to the question of whether society got what it paid for.
Categorized in